The FDA has granted priority review designation for two new drug applications for a selective corticotropin-releasing factor type 1 receptor to treat congenital adrenal hyperplasia, according to a ...
Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. For more information about the Phase 2 TouCAHn study in classic CAH, please visit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback